Acurx Pharmaceuticals Stock (NASDAQ:ACXP)


OwnershipFinancialsChartTranscripts

Previous Close

$1.67

52W Range

$1.18 - $5.28

50D Avg

$1.95

200D Avg

$2.24

Market Cap

$23.48M

Avg Vol (3M)

$46.79K

Beta

-1.72

Div Yield

-

ACXP Company Profile


Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Jun 25, 2021

Website

ACXP Performance


ACXP Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-14.58M$-12.09M$-12.88M
Net Income$-14.58M$-12.09M$-12.68M
EBITDA$-14.58M$-12.09M$-12.88M
Basic EPS$-1.15$-1.12$-1.49
Diluted EPS$-1.15$-1.12$-1.49

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 13, 24 | 11:43 AM
Q2 24Aug 09, 24 | 10:20 AM
Q1 24May 15, 24 | 1:14 PM

Peer Comparison


TickerCompany
ENOBRenovaro Biosciences Inc.
PMVPPMV Pharmaceuticals, Inc.
MNPRMonopar Therapeutics Inc.
MLYSMineralys Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
ANTXAN2 Therapeutics, Inc.
RZLTRezolute, Inc.
CADLCandel Therapeutics, Inc.
SILOSilo Pharma, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ADAGAdagene Inc.
LUMOLumos Pharma, Inc.